Tecentriq, Roche's immunotherapy drug has won its third trial win in a combo with other cancer drugs.
In first-line treatment of patients with advanced squamous non-small cell lung cancer, a late-stage study found that when Tecentriq is mixed with chemotherapies carboplatin and Abraxane, the combo cut risk of disease worsening or death compared to chemotherapy alone. This form of lung cancer accounts for 25-30 percent of lung cancer cases.
Roche is still waiting for overall survival data as it continues the trials. Since December, Roche has demonstrated a benefit for patients getting a Tecentriq combo three times, including against other forms of lung cancer and kidney cancer.
Read the Reuters report